| Comparison | Pathogen | QALY gain | Accepted additional cost | Interpretation |
|---|---|---|---|---|
| Jones 2005 | Intermittent PA | 1.08/clinic (0.004/person) | £21,600/clinic | As long as en suite facilities cost the clinic less than an additional £21,600/year, en suite facilities would still be considered cost-effective relative to shared facilities |
| Jones 2005 (2000, 4.4% versus 2001, 3.3%) | Super infection with chronic PA | 1.05/clinic (0.004/person) | £21,000/clinic | As long as en suite facilities cost the clinic less than an additional £21,000/year, en suite facilities would still be considered costeffective relative to shared facilities |
| Jones 2005 (2000, 4.4% versus average 2001–03, 4.6%) | Super infection with chronic PA | −0.19/clinic (−0.001/person) | −£3,800/clinic | En suite facilities are less effective than shared facilities, as long as en suite cost the clinic less than £3,800/year than shared facilities, the cost saving could outweigh the QALY loss. The ICER would lie in the SW quadrant of the costeffectiveness plane |
ICER, incremental cost-effectiveness ratio; SW, south-west quadrant of the cost-effectiveness plane (less effective and less expensive than the comparator); PA, P aeruginosa; QALY, quality-adjusted life year
From: Appendix K, Health Economics
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.